Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial

Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial

Dendritic cells (DCs) are antigen-presenting cells that are capable of priming anti-tumor immune responses, thus serving as attractive tools to generate tumor vaccines. In this multicentric randomized open-label phase II study, we investigated the efficacy of vaccination with tumor lysate-charged au...

Full description

Bibliographic Details
Main Authors: Johanna Buchroithner, Friedrich Erhart, Josef Pichler, Georg Widhalm, Matthias Preusser, Günther Stockhammer, Martha Nowosielski, Sarah Iglseder, Christian F. Freyschlag, Stefan Oberndorfer, Karin Bordihn, Gord von Campe, Markus Hoffermann, Reinhard Ruckser, Karl Rössler, Sabine Spiegl-Kreinecker, Michael B. Fischer, Thomas Czech, Carmen Visus, Günther Krumpl, Thomas Felzmann, Christine Marosi
Format: Article
Language:English
Published: MDPI AG 2018-10-01
Series:Cancers
Subjects:
glioblastoma
active immunotherapy
dendritic cells
tumor vaccine
phase II
randomized
clinical trial
Online Access:http://www.mdpi.com/2072-6694/10/10/372

Internet

http://www.mdpi.com/2072-6694/10/10/372

Similar Items